Literature DB >> 32964952

Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.

S Barabino1, J M Benitez-Del-Castillo, T Fuchsluger, M Labetoulle, N Malachkova, M Meloni, T P Utheim, M Rolando.   

Abstract

OBJECTIVE: The aim of this review is to summarize the results of a consensus meeting held by a group of experts in dry eye disease (DED) to discuss the importance of tear substitutes in the treatment of DED. The meeting focused especially on the main characteristics of lacrimal substitutes, the development of in vitro models to investigate DED pathophysiology and treatment, the importance of conducting rigorous clinical trials, the requirements of the upcoming European Legislation on medical devices, the advances in the formulation of safer preservatives, the peculiarities of treatment in younger subjects, and the importance of an updated terminology for lacrimal substitutes.
MATERIALS AND METHODS: A literature search was conducted using MEDLINE, with different combinations of pertinent keywords, depending on the subject under discussion, such as "dry eye disease"; "tear substitutes"; "in vitro models"; "ocular surface"; "clinical trials"; "European Regulation"; "preservatives" "younger patients". Also, each author included in the discussion selected articles from their personal library. Using a consensus-based method called nominal group technique to reach a conclusion and proposal for a new classification of eye drops used to improve the tear film and ocular surface epithelia, the experts also conducted a round table meeting.
RESULTS: The new terms proposed by the authors are "wetting agents", "multiple-action tear substitutes" or "ocular surface modulators". The new classification is needed to distinguish eye drops used to improve the tear film and ocular surface epithelia, in line with the new definition of DED, which recognizes the loss of ocular homeostasis, and the creation of a vicious circle of chronic inflammation and ocular damage as fundamental aspects of DED pathophysiology.
CONCLUSIONS: Although tear substitutes have been historically used to provide eye lubrication to the ocular surface, recent advances in the pathophysiology of dry eye disease (DED) clarified that treatment should not just focus on tear film quality or quantity, but address the loss of homeostasis of the ocular surface, blocking the vicious circle of chronic inflammation and ocular damage. Given the scant comparative evidence on tear substitutes currently on the market, further studies should focus on developing new agents, considering the advantages provided by in vitro models, importance of conducting rigorous clinical trials, availability of less harmful preservatives and obligations related to the new European legislation on medical devices. Based on the discussion of these topics, a group of experts held a consensus meeting to identify new and more appropriate terms for different tear substitutes. The proposed terms are wetting agents, multiple-action tear substitutes and ocular surface modulators. Regardless of the agent used, it is important to note that tear substitutes represent one of many options for DED treatment, which should not overlook the psychological aspects of the disease and the peculiarities of younger subjects, who seem to have a higher risk for DED, possibly related to digital devices excessive use.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32964952     DOI: 10.26355/eurrev_202009_22801

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Mussel-Inspired Microgel Encapsulated NLRP3 Inhibitor as a Synergistic Strategy Against Dry Eye.

Authors:  Zhiwei Zha; Qiumeng Chen; Decheng Xiao; Chengjie Pan; Wei Xu; Liangliang Shen; Jianliang Shen; Wei Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-06-01

2.  Shear-Thinning and Temperature-Dependent Viscosity Relationships of Contemporary Ocular Lubricants.

Authors:  Wasim Kapadia; Ning Qin; Pei Zhao; Chau-Minh Phan; Lacey Haines; Lyndon Jones; Carolyn L Ren
Journal:  Transl Vis Sci Technol       Date:  2022-03-02       Impact factor: 3.283

Review 3.  Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease.

Authors:  Marc Labetoulle; Jose Manuel Benitez-Del-Castillo; Stefano Barabino; Rocio Herrero Vanrell; Philippe Daull; Jean-Sebastien Garrigue; Maurizio Rolando
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

Review 4.  A Narrative Review of Current Understanding and Classification of Dry Eye Disease with New Insights on the Impact of Dry Eye during the COVID-19 Pandemic.

Authors:  Stefano Barabino
Journal:  Ophthalmol Ther       Date:  2021-07-17

5.  GlicoPro, Novel Standardized and Sterile Snail Mucus Extract for Multi-Modulative Ocular Formulations: New Perspective in Dry Eye Disease Management.

Authors:  Rita Mencucci; Giovanni Strazzabosco; Virginia Cristofori; Andrea Alogna; Daria Bortolotti; Roberta Gafà; Michela Cennamo; Eleonora Favuzza; Claudio Trapella; Valentina Gentili; Roberta Rizzo
Journal:  Pharmaceutics       Date:  2021-12-13       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.